MODAG GmbH
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
MODAG GmbH - overview
Established
2013
Location
-, -, Germany
Primary Industry
Biotechnology
About
MODAG GmbH develops innovative therapeutics and diagnostics focused on neurodegenerative diseases, particularly targeting Parkinson's disease and Multiple System Atrophy through advanced research and product solutions. Founded in 2013 in Germany, MODAG GmbH specializes in neurodegenerative disease solutions. The company raised EUR 12 million in Series A funding on March 20, 2019, led by Massa Investment AG and including Max Planck Society. The founder's background and additional details about operational pivots are not disclosed.
MODAG Neuroscience Solutions specializes in research and development of therapeutics and diagnostics for neurodegenerative diseases, notably Parkinson's disease and Multiple System Atrophy (MSA). Their main product, Emrusolmin (anle138b), targets harmful alpha-synuclein aggregates to halt disease progression while improving patient quality of life. The company also provides diagnostic services using advanced techniques like PET-Tracer imaging and Seed Amplification Assay (SAA), catering to healthcare providers, research institutions, and pharmaceutical partners globally, particularly in Europe and the United States. MODAG generates revenue through collaborations with pharmaceutical companies including Teva Pharmaceutical Industries Ltd.
and organizations like the Michael J. Fox Foundation. Revenue comes from licensing agreements and research partnerships, further supported by milestone payments and royalties related to their flagship product, Emrusolmin. Additionally, diagnostic procedures utilized in clinical trials may contribute further to revenue streams through hospital and research entity collaborations.
In March 2019, MODAG GmbH raised EUR 12 million in Series A funding, which will support the development of new products and market expansion. The company is focused on designing innovative therapies set to launch in the coming years, aiming to penetrate new geographic markets, specifically targeting increased presence in North America and Asia by 2025. Recent funding will facilitate these initiatives and enhance their market positioning in neurodegenerative disease treatment.
Current Investors
Max Planck Society, Massa Investment AG
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.modag.net
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.